Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Cash & Current Investments (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Cash & Current Investments for 7 consecutive years, with $30.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 72.0% to $30.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.5 million through Dec 2025, down 72.0% year-over-year, with the annual reading at $30.5 million for FY2025, 72.0% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $30.5 million at Strata Critical Medical, down from $75.9 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $333.2 million in Q2 2021, with the low at $7.5 million in Q1 2021.
  • Average Cash & Current Investments over 5 years is $164.3 million, with a median of $152.4 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments surged 266678.07% in 2021, then crashed 72.0% in 2025.
  • Over 5 years, Cash & Current Investments stood at $280.0 million in 2021, then crashed by 45.06% to $153.8 million in 2022, then decreased by 9.37% to $139.4 million in 2023, then fell by 21.8% to $109.0 million in 2024, then plummeted by 72.0% to $30.5 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $30.5 million, $75.9 million, and $56.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.